DelMar Pharmaceuticals to Present Clinical and Preclinical Abstracts for VAL-083 at the American Association of Cancer Research (AACR) Annual Meeting in April 2015 February 24, 2015 • 8:00 AM EST
DelMar Pharmaceuticals Announces December 31, 2014 Financial Results and Provides Corporate Update February 12, 2015 • 8:00 AM EST
DelMar Pharmaceuticals Appoints Lynda Cranston, BScN, MScN, ICD.D, to the Board of Directors February 11, 2015 • 8:13 AM EST
DelMar Pharmaceuticals Completes Offer to Exchange Common Stock for Outstanding Warrants February 10, 2015 • 9:35 AM EST
DelMar Pharmaceuticals Receives Notice of Allowance for Third US Patent for VAL-083 January 13, 2015 • 8:00 AM EST
DelMar Pharmaceuticals Provides Update on VAL-083 Clinical Trial and Outlines Corporate Objectives for 2015 January 12, 2015 • 8:00 AM EST
DelMar Pharmaceuticals Commences Offer to Exchange Common Stock for Outstanding Warrants January 8, 2015 • 8:00 AM EST
DelMar Pharmaceuticals' Promising New Data Support the Potential of VAL-083 to Meet Significant Unmet Medical Needs in the Treatment of Glioblastoma Multiforme November 17, 2014 • 8:00 AM EST